Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties?
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001921:Brain / Q000378:metabolism; D003909:Dexetimide / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D010276:Parasympatholytics / Q000009:adverse effects*; D051381:Rats; D011955:Receptors, Drug / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000378:metabolism
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D011955:Receptors, Drug; D011976:Receptors, Muscarinic; D003909:Dexetimide